ArticleFrontiers in immunology2026
The inhibitory receptor NKG2A is expressed on T-cells during BKPyVANephropathy.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: BKPyV-associated nephropathy (BKPyVAN) is a major complication in kidney transplantation. An exhaustion of BKPyV-specific T-cells but not T-cells against other viruses is observed, suggesting a mechanism specifically mediated by BKPyV-specific CD8 Methods: We analyzed the proliferation and specific functions in response to stimulation with BKPyV or CEF peptides of T-cells from 41 kidney transplants (23 without BKPyV-DNAemia and 18 with presumed BKPyVAN). We performed comparative transcriptomics on peripheral BKPyV-LT-CD8 and EBV-LT-CD8 cells, and kidney biopsy specimens from patients with BKPyVAN and stable transplants (GSE47199 dataset). The factors identified were validated by immunohistochemistry on graft biopsy specimens. Results: Levels of the KLRC1 transcript encoding NKG2A were higher in peripheral BKPyV-LT-CD8 than in EBV-LT-CD8 cells. They were also higher in BKPyVAN than in stable kidneys. Immunohistochemistry revealed a higher quantity of NKG2A Conclusion: These findings identify NKG2A as a checkpoint inhibitor associated with impaired BKPyV-LT-CD8 function in presumed BKPyVAN. The NKG2A/HLA-E pathway therefore plays a key role in BKPyVAN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.